---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-082997"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-07-11T23:59:59+00:00"
generated_at: "2026-05-31T21:44:39.351995+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# KalVista submits NDA for sebetralstat; FY2024 net loss $126.6M

## Summary
- NDA submitted to FDA for sebetralstat, first oral on-demand HAE treatment; potential approval H1 2025.
- FY2024 net loss $126.6M ($3.44/share) vs $92.9M ($3.33) prior year; no revenue.
- Cash, cash equivalents and marketable securities $210.4M, up from $149.4M; raised $150.1M net in Feb 2024 offering.
- R&D expenses $86.2M (prior $80.3M); G&A $54.3M (prior $30.6M) driven by commercial planning and employee costs.
- Promoted Benjamin Palleiko to CEO in March 2024; strategic review of preclinical Factor XIIa program ongoing.

## SEC filing metadata
- accession: 0000950170-24-082997
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-07-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017024082997/0000950170-24-082997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017024082997/kalv-20240711.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-082997
- JSON: https://secwatch.observer/filing/0000950170-24-082997.json
- Plain text: https://secwatch.observer/filing/0000950170-24-082997.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.